Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05034497 · ClinicalTrials.gov registry record · Phase 1
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
A Phase 1 study of Leptomeningeal Metastasis, sponsored by Plus Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 6
- Study locations
NCT05034497 is a Phase 1 study of Leptomeningeal Metastasis that is active but no longer recruiting, run by Plus Therapeutics. The registered enrollment target is 18 participants, below the 58-participant average among 6 other Leptomeningeal Metastasis trials with a reported enrollment target (69% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT05034497, a Phase 1 study of Leptomeningeal Metastasis, is active but no longer recruiting, sponsored by Plus Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open-label Phase I clinical study that will administer a single dose of 186RNL via intraventricular catheter for treatment of Leptomeningeal Metastases (LM).
Conditions Studied
Interventions
- DRUG 186RNL
Study Locations (6)
New York
- Northshore University Hospital - Manhasset
- Lenox Hill Hospital - New York
Texas
- Universiy of Texas Southwestern Medical Center - Dallas
- UT Health Science Center San Antonio / Mays Cancer Center - San Antonio
Illinois
- Northwestern Memorial Hospital Olson Pavilion - Chicago
Ohio
- Ohio State University Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-12-06 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05034497
The ClinicalTrials.gov registry entry for NCT05034497 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 58-participant average among 6 other Leptomeningeal Metastasis trials with a reported enrollment target (69% lower). The listed sponsor is Plus Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leptomeningeal Metastasis appearing as the primary indexed condition, and to 1 intervention - of which 186RNL is the first listed.
NCT05034497 reports 6 study locations spanning 4 distinct geographic areas - top geographies include New York, Texas, Illinois.
Frequently Asked Questions
What is clinical trial NCT05034497 about?
NCT05034497 is a clinical study titled "Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases". This is an open-label Phase I clinical study that will administer a single dose of 186RNL via intraventricular catheter for treatment of Leptomeningeal Metastases (LM).
What is the current status of trial NCT05034497?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2021-12-06. Estimated completion is 2026-06-30.
What conditions does trial NCT05034497 study?
This clinical trial studies the following conditions: Leptomeningeal Metastasis.
What interventions are being tested in trial NCT05034497?
The interventions under investigation include: 186RNL (DRUG).
Who is sponsoring clinical trial NCT05034497?
This trial is sponsored by Plus Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05034497 being conducted?
This trial has 6 study locations across Illinois, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leptomeningeal Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
RECRUITING · Phase 1
-
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
RECRUITING · Phase 1
-
GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases
ACTIVE NOT RECRUITING · Phase 1
-
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
RECRUITING · Phase 2
-
Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.